La catena delle opzioni mostra i dati chiave delle opzioni azionarie di UnitedHealth Group a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per UnitedHealth Group..

UnitedHealth Group (NYSE:UNH) Azioni, Catena delle Opzioni

UNITEDHEALTH GROUP INC

UnitedHealth Group

UnitedHealth Group is one of the largest private health insurers and provides medical benefits to about 51 million members globally, including 1 million outside the US as of December 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in medical insurance. Along with its insurance assets, UnitedHealth's Optum franchises help create a healthcare services colossus that spans everything from pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.

Jim Cramer- AI Is Bigger Than Rate Cuts

Long Ideas

News

Markets

Media

Trading Ideas

CHDN

DELL

SMCI

Il noto commentatore finanziario ha rilasciato valutazioni incisive su alcuni nomi del mercato, offrendo indicazioni preziose.

Azioni sotto la lente d&#39;ingrandimento di Jim Cramer: ecco cosa ha detto alla CNBC

Irving,,Texas,,Usa,-,March,20,,2022:,Unitedhealthcare,Sign,On

Pre-Market Outlook

XFOR

Indicatori tecnici evidenziano che alcune aziende del comparto potrebbero offrire punti d&#39;ingresso interessanti dopo recenti ribassi.

Sanità: 3 azioni ipervendute da monitorare ad aprile

Netflix

Earnings

NFLX

Report trimestrali per big streaming e colosso sanitario. Attenzione anche a chipmaker, banca regionale e settore housing giovedì.

Netflix, UnitedHealth e altri 3 titoli da tenere d&#39;occhio giovedì

UnitedHealth Group Incorporated Common Stock (DE)

UnitedHealth Group Inc

EC Healthcare

United Hampshire US REIT

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NTRA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$175.00</td>
<td>$36.9K</td>
<td>10</td>
<td>1.3K</td>
</tr>
<tr>
<td>TEVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$18.00</td>
<td>$25.4K</td>
<td>49.9K</td>
<td>898</td>
</tr>
<tr>
<td>SRDX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$30.00</td>
<td>$190.0K</td>
<td>502</td>
<td>500</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$310.00</td>
<td>$43.5K</td>
<td>3.0K</td>
<td>494</td>
</tr>
<tr>
<td>AKBA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$2.50</td>
<td>$31.0K</td>
<td>438</td>
<td>350</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$70.00</td>
<td>$88.3K</td>
<td>576</td>
<td>217</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$710.00</td>
<td>$63.4K</td>
<td>25</td>
<td>13</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$115.00</td>
<td>$87.5K</td>
<td>12</td>
<td>10</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/18/26</td>
<td>$120.00</td>
<td>$35.6K</td>
<td>0</td>
<td>5</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For NTRA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>), we notice a call option trade that happens to be bullish, expiring in 107 day(s) on September 19, 2025. This event was a transfer of 26 contract(s) at a $175.00 strike. The total cost received by the writing party (or parties) was $36.9K, with a price of $1420.0 per contract. There were 10 open contracts at this strike prior to today, and today 1350 contract(s) were bought and sold. 
• For TEVA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>), we notice a call option sweep that happens to be bullish, expiring in 16 day(s) on June 20, 2025. This event was a transfer of 750 contract(s) at a $18.00 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $25.4K, with a price of $34.0 per contract. There were 49987 open contracts at this strike prior to today, and today 898 contract(s) were bought and sold. 
• Regarding SRDX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>), we observe a call option trade with bullish sentiment. It expires in 72 day(s) on August 15, 2025. Parties traded 500 contract(s) at a $30.00 strike. The total cost received by the writing party (or parties) was $190.0K, with a price of $380.0 per contract. There were 502 open contracts at this strike prior to today, and today 500 contract(s) were bought and sold. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a call option sweep with bullish sentiment. It expires in 44 day(s) on July 18, 2025. Parties traded 38 contract(s) at a $310.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $43.5K, with a price of $1145.0 per contract. There were 3038 open contracts at this strike prior to today, and today 494 contract(s) were bought and sold. 
• Regarding AKBA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>), we observe a call option trade with bullish sentiment. It expires in 226 day(s) on January 16, 2026. Parties traded 200 contract(s) at a $2.50 strike. The total cost received by the writing party (or parties) was $31.0K, with a price of $155.0 per contract. There were 438 open contracts at this strike prior to today, and today 350 contract(s) were bought and sold. 
• Regarding MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we observe a call option trade with bearish sentiment. It expires in 16 day(s) on June 20, 2025. Parties traded 100 contract(s) at a $70.00 strike. The total cost received by the writing party (or parties) was $88.3K, with a price of $883.0 per contract. There were 576 open contracts at this strike prior to today, and today 217 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a call option trade that happens to be bullish, expiring in 198 day(s) on December 19, 2025. This event was a transfer of 5 contract(s) at a $710.00 strike. The total cost received by the writing party (or parties) was $63.4K, with a price of $12690.0 per contract. There were 25 open contracts at this strike prior to today, and today 13 contract(s) were bought and sold. 
• For MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we notice a put option sweep that happens to be neutral, expiring in 226 day(s) on January 16, 2026. This event was a transfer of 10 contract(s) at a $115.00 strike. This particular put needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $87.5K, with a price of $8753.0 per contract. There were 12 open contracts at this strike prior to today, and today 10 contract(s) were bought and sold. 
• For ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we notice a call option trade that happens to be neutral, expiring in 471 day(s) on September 18, 2026. This event was a transfer of 5 contract(s) at a $120.00 strike. The total cost received by the writing party (or parties) was $35.6K, with a price of $7130.0 per contract. There were 0 open contracts at this strike prior to today, and today 5 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ABBV

AKBA

MRNA

NTRA

SRDX

TEVA

9 Health Care Stocks Whale Activity In Today's Session

UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) re-elected all current directors on Wednesday. The board authorized the payment of a cash dividend of $2.21 per share, up from the <a href="https://www.unitedhealthgroup.com/investors/stock.html" target="_blank" rel="noopener">prior</a> dividend of $2.10, to be paid June 24 to common stock shareholders of record as of the close of <a href="https://www.benzinga.com/pressreleases/25/06/b45766386/unitedhealth-group-updates-on-annual-shareholder-meeting-board-actions" target="_blank" rel="noreferrer noopener">business June 16</a>.
In May, UnitedHealth Group&#8217;s CEO&nbsp;, Andrew Witty,&nbsp;resigned for personal reasons. Stephen Hemsley, who previously held the CEO title from 2006 to 2017,&nbsp;<a target="_blank" href="https://www.benzinga.com/25/05/45373368/unitedhealth-stock-plunges-names-new-ceo-suspends-2025-guidance" rel="noreferrer noopener">succeeded him</a>. The company also suspended its 2025 outlook.
In an SEC filing on Wednesday, UnitedHealth <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/731766/000073176625000154/unh-20250602.htm" target="_blank" rel="noreferrer noopener">said</a> it canceled the performance-based restricted stock units granted to Witty,
Year to date, UnitedHealth Group&#8217;s stock has plunged almost 40%, with the majority coming after the disappointing fourth-<a href="https://www.benzinga.com/general/health-care/25/01/43025159/unitedhealth-q4-earnings-revenue-falls-short-medical-ratio-rises-to-85-5-stock-falls" target="_blank" rel="noreferrer noopener">quarter 2024 earnings</a>.
Also Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45687019/unh-stock-broken-contrarian-traders-eyeball-recovery" target="_blank" rel="noreferrer noopener">Options Corner: UnitedHealth May Be Broken But Contrarian Traders Eyeball A Recovery</a>
UnitedHealth&#8217;s aggressive growth strategy under Witty exposed the healthcare giant to mounting regulatory scrutiny, soaring costs, and a <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">shifting Medicare landscape</a>.
UnitedHealth plans to enlist independent experts to examine its Medicare billing practices, which were criticized following a Wall Street Journal <a href="https://www.benzinga.com/general/health-care/25/05/45443695/why-is-unitedhealth-stock-trading-lower-on-thursday" target="_blank" rel="noreferrer noopener">investigation last year</a>.
Hemsley is stepping forward to acknowledge the fallout and chart a new course, promising a comprehensive review of some of the company's most controversial practices.
The Wall Street Journal noted in its report on the company's annual shareholder meeting on Monday that Hemsley apologized for UnitedHealth's recent performance and cited a need to rethink many internal processes.
He said the company has factored recent results into its 2025 Medicare bids and emphasized a "fresh perspective" on issues that have drawn widespread criticism.
Under Witty, UnitedHealth scaled up its dominance in Medicare Advantage, the privately managed alternative to traditional Medicare.
Former employees said UnitedHealth's profit margins on Medicare enrollees were roughly double those of traditional Medicare insurers.
That advantage stemmed partly from federal rules that limit the premium revenue pure insurers can keep. Additionally, the government pays more for patients with certain chronic diagnoses—a system UnitedHealth capitalized on by gathering such data at high rates.
However, changes announced by the Medicare agency in 2023 altered the rules, reducing or eliminating extra payments for many diagnoses. The changes, phased in starting this year, were expected to have a major financial impact.
An internal analysis <a target="_blank" href="https://www.wsj.com/health/healthcare/unitedhealth-ceo-andrew-witty-medicare-dde1964c" rel="noreferrer noopener">viewed</a> by the WSJ indicated the new rules would significantly reduce the number of reimbursable chronic diagnoses for nearly 900,000 patients.
Despite this, UnitedHealth continued betting on Medicare growth for 2025, even in high-risk patient segments, while rivals pulled back following profit hits in 2024 tied to rising costs.
Hemsley said the company would also examine its pharmacy services and managed care policies, including prior authorization—a process that has faced growing criticism from physicians and patients.
Price Action: UNH stock was flat at $301.29 at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/06/45768682/dollar-tree-q1-same-store-sales-jump-5-4-warns-of-near-term-profit-drop-on-tariff-pressure-transition-costs" target="_blank" rel="noreferrer noopener">Dollar Tree Q1 Same-Store Sales Jump 5.4%, Warns Of Near-Term Profit Drop On Tariff Pressure, Transition Costs</a></li>
</ul>
Photo: Piotr Swat / Shutterstock.com

Large Cap

Dividends

Health Care

Management

Movers

General

UnitedHealth Board Reelects Directors, Hikes Dividend As CEO Pledges Review Of Medicare Practices

<ul>
<li>CRWV</li>
<li>HOOD</li>
<li>ADP</li>
<li>TSLA</li>
<li>NVDA</li>
<li>GLD</li>
<li>GOOGL</li>
<li>UMH</li>
<li>RDDT</li>
<li>AAPL</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

AAPL

CRWV

GOOGL

HOOD

NVDA

RDDT

TSLA

Top 10 Trending Stocks On WallStreetBets As Of June 4, 2025 (Via Swaggy Stocks)

UnitedHealth Hikes Quarterly Dividend To $2.21 From $2.10 Per Share

Unitedhealth Shareholders Re-elected All Current Directors And Authorized Payment Of A Cash Dividend Of $2.21 Per Share, To Be Paid June 24, 2025, To Shareholders Of Record As Of June 16, 2025

Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0603" target="_blank" rel="noreferrer noopener">&nbsp;and individual tickers.</a>
Here is a look at the most searched stocks on Benzinga Pro for May 2025. Current prices and year-to-date performance are based on May 30 market close prices and do not include dividends.
1. SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)
<ul class="wp-block-list">
<li>Current Price: $589.39</li>
<li>52-Week Range: $481.81 to $613.23</li>
<li>Year-to-Date Return: +0.8%</li>
<li><a href="https://www.benzinga.com/trading-ideas/25/01/42802731/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-2024-where-do-tesla-nvidia-gamestop-trump-media-stocks-rank">2024 Benzinga Pro Search Rank</a>: 3rd</li>
<li><a href="https://www.benzinga.com/trading-ideas/25/03/44124338/exclusive-februarys-20-most-searched-tickers-on-benzinga-pro-where-do-tesla-palantir-alibaba-nvidia-rank">February</a>/<a href="https://www.benzinga.com/trading-ideas/25/04/44597684/exclusive-marchs-20-most-searched-tickers-on-benzinga-pro-where-do-tesla-nvidia-apple-applovin-stock-rank">March</a>/<a href="https://www.benzinga.com/trading-ideas/25/05/45171636/exclusive-aprils-20-most-searched-tickers-on-benzinga-pro-where-do-tesla-apple-palantir-nvidia-stocks-rank">April </a>2025 Rank: 3rd/2nd/1st</li>
</ul>
2. NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)
<ul class="wp-block-list">
<li>Current Price: $135.13</li>
<li>52-Week Range: $86.62 to $153.13</li>
<li>Year-to-Date Return: -2.3%</li>
<li>2024 Benzinga Pro Search Rank: 1st</li>
<li>February/March/April 2025 Rank: 2nd/3rd/2nd</li>
</ul>
3. Palantir Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>)
<ul class="wp-block-list">
<li>Current Price: $131.78</li>
<li>52-Week Range: $21.00 to $133.49</li>
<li>Year-to-Date Return: +75.3%</li>
<li>2024 Benzinga Pro Search Rank: 7th</li>
<li>February/March/April 2025 Rank: 4th/6th/7th</li>
</ul>
4. Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
<ul class="wp-block-list">
<li>Current Price: $346.46</li>
<li>52-Week Range: $167.41 to $488.54</li>
<li>Year-to-Date Return: -8.7%</li>
<li>2024 Benzinga Pro Search Rank: 2nd</li>
<li>February/March/April 2025 Rank: 5th/1st/3rd</li>
</ul>
5. UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)
<ul class="wp-block-list">
<li>Current Price: $301.91</li>
<li>52-Week Range: $248.88 to $630.73</li>
<li>Year-to-Date Return: -40.2%</li>
<li>2024 Benzinga Pro Search Rank: Not in Top 20</li>
<li>February/March/April 2025 Rank: Not in Top 20/Not in Top 20/Not in Top 20</li>
</ul>
6. Asset Entities (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASST#NASDAQ">ASST</a>)
<ul class="wp-block-list">
<li>Current Price: $7.01</li>
<li>52-Week Range: $0.34 to $13.42</li>
<li>Year-to-Date Return:1,330.6%</li>
<li>2024 Benzinga Pro Search Rank: Not in Top 20</li>
<li>February/March/April 2025 Rank: Not in Top 20/Not in Top 20/Not in Top 20</li>
</ul>
7. Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)
<ul class="wp-block-list">
<li>Current Price: $40.02</li>
<li>52-Week Range: $17.25 to $101.40</li>
<li>Year-to-Date Return: +33.2%</li>
<li>2024 Benzinga Pro Search Rank: 4th</li>
<li>February/March/April 2025 Rank: 1st/9th/Not in Top 20</li>
</ul>
8. D-Wave Quantum Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>)
<ul class="wp-block-list">
<li>Current Price: $16.33</li>
<li>52-Week Range: $0.75 to $19.76</li>
<li>Year-to-Date Return: +69.9% &nbsp;</li>
<li>2024 Benzinga Pro Search Rank: Not in Top 20</li>
<li>February/March/April 2025 Rank: Not in Top 20/10th/Not in Top 20</li>
</ul>
9. Hims &amp; Hers Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>)
<ul class="wp-block-list">
<li>Current Price: $56.56</li>
<li>52-Week Range: $13.47 to $72.98</li>
<li>Year-to-Date Return: +124.4%</li>
<li>2024 Benzinga Pro Search Rank: 5th</li>
<li>February/March/April 2025 Rank: 16th/8th/8th</li>
</ul>
10. Apple Inc (NASDSAQ:AAPL)
<ul class="wp-block-list">
<li>Current Price: $200.85</li>
<li>52-Week Range: $169.21 to $260.10</li>
<li>Year-to-Date Return: -17.6%</li>
<li>2024 Benzinga Pro Search Rank: 5th</li>
<li>February/March/April 2025 Rank: 16th/8th/8th</li>
</ul>
Did You Know?
<ul class="wp-block-list">
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent060325">Get Tips On What They Bought And Sold With Our Easy-to-Use Tool</a></li>
</ul>
Honorable Mentions:&nbsp;The following stocks were the 11th&nbsp;to 20th&nbsp;most-searched tickers on&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent030425&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;in May.
11. CoreWeave Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>)
12. Oklo Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>)
13. SharpLink Gaming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>)
14. Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>)
15. Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)
16. Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)
17. Coinbase Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>)
18. Siyata Mobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYTA#NASDAQ">SYTA</a>)
19. Hyperscale Data (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GPUS#AMEX">GPUS</a>)
20. Pony AI Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>)
Why It's Important: The SPDR S&amp;P 500 ETF Trust remained the most-searched ticker for a second straight month. Nvidia also ranked second for a second straight month.
New to the top three in May was Palantir, which jumped from seventh place in April to third place in May. The ticker has been popular among investors and ranked in the top 10 each month this year. The third-place ranking is the top for Palantir in 2025.
Tesla fell from third to fourth place, following a fall in April from first to third place. With the highly anticipated launch of Tesla robotaxis in June, the stock could attract more attention and find its way back into the top three spots.
The list of the top 10 most-searched tickers in May included five new stocks compared to the list from April. This included Super Micro Computer jumping back into the top 10 after falling out of the top 20 in April. The stock has been popular among investors this year and saw its highest place on the list since February during the month of May.
D-Wave, a quantum computing stock, also returned to the top 10, ranking 8th in May. Hims &amp; Hers also moved back into the top 10, ranking ninth after previously being outside the top 20 in March and April and ranking 9th in February.
New to the top 10 in May that hadn't been in the top 20 any month this year were United Health and Asset Entities. United Health saw an executive transition announced and was reported to be the subject of a DOJ investigation, a claim the company later denied.
Asset Entities announced a merger and plans to become a Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) <a href="https://www.benzinga.com/25/05/45550814/asset-entities-stock-has-skyrocketed-over-the-last-month-whats-going-on">holding treasury company</a>. SharpLink, which ranked 13th, also made a similar announcement but instead of investing in Bitcoin, the company <a href="https://www.benzinga.com/cannabis/25/05/45695750/sharplink-gaming-sbet-stock-soars-over-2600-in-a-week-on-ethereum-treasury-deal">is establishing an </a>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) treasury.
CoreWeave, which went public on March 28, narrowly missed out on the top 10 with an 11th-place ranking for the month of May. The ranking could signal continued popularity for the cloud computing company a month after its IPO.
Advanced Micro Devices, Invesco QQQ Trust and Amazon.com were the three tickers in the 11th to 20th rankings that previously ranked in the top 20 in April, coming in at 18th, 4th and 13th, respectively.
This marked a significant fall for the Invesco QQQ Trust, which ranked fourth in March and April. This could signal less interest in the Nasdaq 100 and technology stocks during the month.
Stay tuned <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0603">to Benzinga Pro </a>for more market-moving news and to track the top tickers. 
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/space/25/05/45680115/tesla-the-best-elon-musk-company-84-say-no-these-3-rank-higher">Tesla The Best Elon Musk Company? 84% Say No — These 3 Rank Higher</a></li>
</ul>
Photo: Shutterstock

Topics

Exclusives

$BTC

$ETH

AMZN

ASST

COIN

GPUS

Hims & Hers Health, Inc. Class A Common Stock

HIMS

OKLO

PLTR

PONY

QBTS

SBET

SYTA

EXCLUSIVE: May's 20 Most-Searched Tickers On Benzinga Pro — Where Do Apple, Palantir, CoreWeave, Nvidia Rank?

Records from June 2, 2025 indicate that Representative David Taylor of Ohio made a sale of UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), valued between $18,004 and $95,000, with the transaction dated May 14, 2025 and filed in June.
As of now, UnitedHealth Group shares are trading down 0.32% at $303.73.
<h3>What Representative Has Been Trading Recently</h3>
In the last three years, David Taylor completed 21 stock transactions totaling more than $35 thousand. UnitedHealth Group and Amazon.com stocks were among the largest trades. Some of the most notable transactions the Rep. has executed recently include: 
<ul>
<li>UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>): $15,001 - $50,000 Sale</li>
<li>Installed Building Prods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBP#NYSE">IBP</a>): $1,001 - $15,000 Purchase</li>
<li>Broadcom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>): $1,001 - $15,000 Purchase</li>
</ul>
Here's a summary of David Taylor's recent trades:
<table>
<thead>
<tr>
<th>Company</th>
<th>Ticker</th>
<th>Stock Type</th>
<th>Amount</th>
<th>Transaction Type</th>
<th>Transaction Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Installed Building Prods</td>
<td>IBP</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2025-05-15</td>
</tr>
<tr>
<td>Broadcom</td>
<td>AVGO</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2025-05-14</td>
</tr>
<tr>
<td>Fifth Third Bancorp</td>
<td>FITB</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2025-05-14</td>
</tr>
<tr>
<td>UnitedHealth Group</td>
<td>UNH</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>S</td>
<td>2025-05-14</td>
</tr>
<tr>
<td>UnitedHealth Group</td>
<td>UNH</td>
<td>STOCK</td>
<td>$15,001 - $50,000</td>
<td>S</td>
<td>2025-05-14</td>
</tr>
</tbody>
</table>
To keep an eye on David Taylor's trades and other government stock activity, check out our <a href="https://www.benzinga.com/gov-trades/members/david-taylor">real-time tracking tool</a>!
<h3>Why Congressional Transactions Matter</h3>
A congressional transaction is when any representative or senator either buys or sells an individual stock.
Anyone working in Congress must file a Periodic Transaction Report to inform the public of their recent transaction within 30 days of being notified of the transaction and within 45 days of the transaction date.
In April 2012, Former President Barack Obama signed the STOCK Act into law. The act prohibits members of Congress from using private information given to them by their position for personal gain such as buying or selling a stock. The act also expanded disclosure requirements for members of Congress by requiring them to file a monthly disclosure.
<h3>The Importance of Congressional Transactions</h3>
Congressional transactions shouldn't be the primary reason for an investing decision, but they can be an important factor for an investor to consider.
When a senator or representative makes a new purchase, it could be an indication they expect the stock to rise.
A sale, on the other hand, can be made for a variety of reasons, and may not necessarily mean the seller thinks the stock will go down.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Government

Politics

AVGO

A Congress Member Sold Up To $95K In UnitedHealth Group Stock: Here's What You Need To Know

Piper Sandler analyst Jessica Tassan maintains UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) with a Overweight and lowers the price target from $552 to $353.

Price Target

Analyst Ratings

Piper Sandler Maintains Overweight on UnitedHealth Group, Lowers Price Target to $353

<ul>
<li>GOOGL</li>
<li>GLD</li>
<li>TSLA</li>
<li>UNH</li>
<li>NVDA</li>
<li>GOOG</li>
<li>HOOD</li>
<li>BULL</li>
<li>SLV</li>
<li>HIMS</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

BULL

GOOG

Top 10 Trending Stocks On WallStreetBets As Of June 3, 2025 (Via Swaggy Stocks)

Providing a diverse range of perspectives from bullish to bearish, 29 analysts have published ratings on UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) in the last three months.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">21</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">10</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $448.07, a high estimate of $660.00, and a low estimate of $270.00. This current average represents a 21.7% decrease from the previous average price target of $572.24. 
<img src="https://www.benzinga.com/files/images/story/2025/1748890833_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of UnitedHealth Group among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$350.00</td>
<td>$362.00</td>
</tr>
<tr>
<td>Matthew Gillmor</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$400.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Sidharth Sahoo</td>
<td>HSBC</td>
<td>Lowers</td>
<td>Reduce</td>
<td>$270.00</td>
<td>$490.00</td>
</tr>
<tr>
<td>Justin Lake</td>
<td>Wolfe Research</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$390.00</td>
<td>$501.00</td>
</tr>
<tr>
<td>Ryan Langston</td>
<td>TD Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$308.00</td>
<td>$520.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$360.00</td>
<td>$580.00</td>
</tr>
<tr>
<td>Ann Hynes</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$350.00</td>
<td>$515.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$355.00</td>
<td>$525.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$362.00</td>
<td>$513.00</td>
</tr>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$405.00</td>
<td>$525.00</td>
</tr>
<tr>
<td>George Hill</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Buy</td>
<td>$362.00</td>
<td>$521.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$400.00</td>
<td>$600.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$351.00</td>
<td>$677.00</td>
</tr>
<tr>
<td>Ricky Goldwasser</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$374.00</td>
<td>$563.00</td>
</tr>
<tr>
<td>Kevin Fischbeck</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$350.00</td>
<td>$560.00</td>
</tr>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$356.00</td>
<td>$510.00</td>
</tr>
<tr>
<td>Matthew Gillmor</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$450.00</td>
<td>$575.00</td>
</tr>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$510.00</td>
<td>$640.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$513.00</td>
<td>$560.00</td>
</tr>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$525.00</td>
<td>$652.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$525.00</td>
<td>$655.00</td>
</tr>
<tr>
<td>Ricky Goldwasser</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$563.00</td>
<td>$664.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$580.00</td>
<td>$660.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$560.00</td>
<td>$642.00</td>
</tr>
<tr>
<td>Tim Rezvan</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$575.00</td>
<td>$650.00</td>
</tr>
<tr>
<td>John Ransom</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$540.00</td>
<td>$635.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$600.00</td>
<td>$640.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$660.00</td>
<td>$610.00</td>
</tr>
<tr>
<td>Ann Hynes</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$650.00</td>
<td>$600.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to UnitedHealth Group. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of UnitedHealth Group compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of UnitedHealth Group's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of UnitedHealth Group's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/UNH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on UnitedHealth Group analyst ratings.</a>
<h2>Delving into UnitedHealth Group's Background</h2>
UnitedHealth Group is one of the largest private health insurers and provides medical benefits to about 51 million members globally, including 1 million outside the US as of December 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in medical insurance. Along with its insurance assets, UnitedHealth's Optum franchises help create a healthcare services colossus that spans everything from pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
<h3>A Deep Dive into UnitedHealth Group's Financials</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: UnitedHealth Group displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 9.8%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: UnitedHealth Group's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.74% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): UnitedHealth Group's ROE excels beyond industry benchmarks, reaching 6.7%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): UnitedHealth Group's ROA stands out, surpassing industry averages. With an impressive ROA of 2.07%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: UnitedHealth Group's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.86.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 29 Analyst Projections For UnitedHealth Group

Wathing UnitedHealth Group; During Shareholder Meeting, CEO Reportedly Says Co Has Incorporated Elevated Care Activity Experience Into The Medicare Advantage Bids Submitted To CMS This Week; Will Continue To Incorporated Elevated Care Activity Experience Into Pricing For Commercial Plans

Barclays analyst Andrew Mok maintains UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) with a Overweight and lowers the price target from $362 to $350.

Barclays Maintains Overweight on UnitedHealth Group, Lowers Price Target to $350

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Truist Securities raised Dollar Tree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) price target from $89 to $100. Truist Securities analyst Scot Ciccarelli maintained a Buy rating. Dollar Tree shares closed at $90.26 on Friday. See how other analysts <a href="https://www.benzinga.com/quote/DLTR/analyst-ratings">view this stock</a>.</li>
<li>Keybanc slashed the price target for UnitedHealth Group Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) from $450 to $400. Keybanc analyst Matthew Gillmor maintained an Overweight rating. UnitedHealth shares closed at $301.91 on Friday. <a href="https://www.benzinga.com/quote/UNH/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Raymond James raised Block, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) price target from $74 to $79. Raymond James analyst John Davis maintained an Outperform rating. Block shares closed at $61.75 on Friday. See how other analysts <a href="https://www.benzinga.com/quote/xyz/analyst-ratings">view this stock</a>.</li>
<li>Wedbush increased the price target for Blueprint Medicines Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) from $128 to $129. Wedbush analyst David Nierengarten downgraded the stock from Outperform to Neutral. Blueprint Medicines shares closed at $101.35 on Friday. <a href="https://www.benzinga.com/quote/bpmc/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Mizuho increased the price target for SolarEdge Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) from $15 to $18. Mizuho analyst Maheep Mandloi maintained a Neutral rating. SolarEdge Technologies shares closed at $17.86 on Friday. <a href="https://www.benzinga.com/quote/sedg/analyst-ratings">See how other analysts view this stock.</a></li>
<li>UBS raised SPX Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPXC#NYSE">SPXC</a>) price target from $160 to $182. UBS analyst Damian Karas upgraded the stock from Neutral to Buy. SPX Technologies shares settled at $152.09 on Friday. <a href="https://www.benzinga.com/quote/spxc/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley increased EOG Resources, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EOG#NYSE">EOG</a>) price target from $132 to $135. Morgan Stanley analyst Devin McDermott maintained an Equal-Weight rating. EOG Resources shares closed at $108.57 on Friday. <a href="https://www.benzinga.com/quote/eog/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Jefferies raised Rollins, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROL#NYSE">ROL</a>) price target from $55 to $65. Jefferies analyst Stephanie Moore upgraded the stock from Hold to Buy. Rollins shares closed at $57.24 on Friday.  <a href="https://www.benzinga.com/quote/rol/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities increased the price target for The Boeing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) from $185 to $260. B of A Securities analyst Ronald Epstein upgraded the stock from Neutral to Buy. Boeing shares settled at $207.29 on Friday. <a href="https://www.benzinga.com/quote/ba/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs raised Knight-Swift Transportation Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNX#NYSE">KNX</a>) price target from $45 to $65. Goldman Sachs analyst Jordan Alliger upgraded the stock from Neutral to Buy. Knight-Swift Transportation shares closed at $44.32 on Friday. <a href="https://www.benzinga.com/quote/knx/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying BA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="579" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02093559/image-11-1024x579.png" alt="" class="wp-image-935238" style="width:628px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02093559/image-11-1024x579.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02093559/image-11-300x170.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02093559/image-11-768x434.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02093559/image-11.png 1167w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45719208/cramer-shouldve-told-investors-to-pull-the-trigger-on-trade-desk-cant-believe-how-low-gentex-has-fallen">Cramer: Should&#8217;ve Told Investors To &#8216;Pull The Trigger&#8217; On Trade Desk, Can&#8217;t Believe &#8216;How Low&#8217; Gentex Has Fallen</a> </li>
</ul>
Photo via Shutterstock

BPMC

DLTR

SEDG

SPXC

Boeing To Rally More Than 25%? Here Are 10 Top Analyst Forecasts For Monday

Keybanc analyst Matthew Gillmor maintains UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) with a Overweight and lowers the price target from $450 to $400.

Keybanc Maintains Overweight on UnitedHealth Group, Lowers Price Target to $400

<ul>
<li>TSLA</li>
<li>GLD</li>
<li>UNH</li>
<li>NVDA</li>
<li>GOOGL</li>
<li>GOOG</li>
<li>CLF</li>
<li>PLTR</li>
<li>BULL</li>
<li>RDDT</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

Top 10 Trending Stocks On WallStreetBets As Of June 2, 2025 (Via Swaggy Stocks)

Investors with a lot of money to spend have taken a bullish stance on UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with UNH, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 30 uncommon options trades for UnitedHealth Group.
This isn't normal.
The overall sentiment of these big-money traders is split between 60% bullish and 33%, bearish.
Out of all of the special options we uncovered, 9 are puts, for a total amount of $399,930, and 21 are calls, for a total amount of $1,388,209.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $250.0 and $630.0 for UnitedHealth Group, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for UnitedHealth Group's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of UnitedHealth Group's whale activity within a strike price range from $250.0 to $630.0 in the last 30 days. 
<h3>UnitedHealth Group Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748628123_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$12.15</td>
<td>$10.4</td>
<td>$10.75</td>
<td>$360.00</td>
<td>$387.0K</td>
<td>1.1K</td>
<td align="right">360</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$14.1</td>
<td>$14.05</td>
<td>$14.1</td>
<td>$400.00</td>
<td>$176.2K</td>
<td>9.5K</td>
<td align="right">291</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$6.8</td>
<td>$6.6</td>
<td>$6.75</td>
<td>$310.00</td>
<td>$118.1K</td>
<td>3.6K</td>
<td align="right">248</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$22.5</td>
<td>$22.05</td>
<td>$22.5</td>
<td>$350.00</td>
<td>$112.5K</td>
<td>3.7K</td>
<td align="right">57</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/17/26</td>
<td>$87.4</td>
<td>$83.3</td>
<td>$87.4</td>
<td>$250.00</td>
<td>$87.4K</td>
<td>128</td>
<td align="right">10</td>
</tr>
</tbody>
</table>

<h3>About UnitedHealth Group</h3>
UnitedHealth Group is one of the largest private health insurers and provides medical benefits to about 51 million members globally, including 1 million outside the US as of December 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in medical insurance. Along with its insurance assets, UnitedHealth's Optum franchises help create a healthcare services colossus that spans everything from pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Following our analysis of the options activities associated with UnitedHealth Group, we pivot to a closer look at the company's own performance.
<h3>Where Is UnitedHealth Group Standing Right Now?</h3>
<ul>
<li>With a trading volume of 9,505,317, the price of UNH is up by 0.97%, reaching $301.07.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 46 days from now.</li>
</ul>
<h3>What Analysts Are Saying About UnitedHealth Group</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $355.4.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Keybanc has decided to maintain their Overweight rating on UnitedHealth Group, which currently sits at a price target of $450. 
&#x2A; An analyst from Baird has decided to maintain their Outperform rating on UnitedHealth Group, which currently sits at a price target of $356. 
&#x2A; An analyst from Wells Fargo persists with their Overweight rating on UnitedHealth Group, maintaining a target price of $351. 
&#x2A; An analyst from B of A Securities has revised its rating downward to Neutral, adjusting the price target to $350. 
&#x2A; Reflecting concerns, an analyst from HSBC lowers its rating to Reduce with a new price target of $270.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for UnitedHealth Group with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

What the Options Market Tells Us About UnitedHealth Group

<ul>
<li>NVDA</li>
<li>GLD</li>
<li>TSLA</li>
<li>GRND</li>
<li>UNH</li>
<li>BULL</li>
<li>GOOGL</li>
<li>ULTA</li>
<li>DELL</li>
<li>AAPL</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

GRND

ULTA

Top 10 Trending Stocks On WallStreetBets As Of May 30, 2025 (Via Swaggy Stocks)

To deny that healthcare giant UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) is struggling would be to categorically ignore reality. Since the start of the year, UNH stock dropped more than 41% of market value, an ignominious decline for a blue chip. At the same time, because it's such a revered name (at least prior to the controversies), investors may be tempted to buy the dip.
Presenting a deep dive into the problems impacting UNH stock would take volumes of printed literature. In a nutshell, the sector juggernaut lost nearly $140 billion of market capitalization following a <a href="https://www.benzinga.com/25/05/45558758/as-unitedhealth-group-lost-an-unthinkable-140-billion-in-market-cap-since-april-analysts-weigh-in-on-the-path-ahead">series of awful news items</a>, including downbeat first-quarter results, CEO Andrew Witty stepping down from the helm and a potential criminal investigation by the Department of Justice.
Analysts expressed shock at the dramatic paradigm shift. "This is a stock that every growth-oriented portfolio manager in the world owned for a decade and made money on it like clockwork," said Whit Mayo from Leerink Partners. "It&#8217;s stunning. It&#8217;s unthinkable," the expert added.
Subsequently, many traders have also rushed for the exits and have largely decided to stay on the sidelines. Currently, UNH stock is <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45627855/whats-going-on-with-unitedhealth-stock-today">trading below key moving averages</a> — common benchmarks to gauge market health. Further, other indicators used by technical analysts, such as the Relative Strength Indicator and the Moving Average Convergence-Divergence (MACD) broadcast deflated momentum.
Still, not everything is pointed in the negative direction. Fundamentally, UnitedHealth added 700,000 new clients in the latest quarter thanks to the vertical integration of UnitedHealthcare and Optum. And while there are legitimate concerns regarding rising healthcare costs and heightened regulations, bullish investors note that UNH stock is undervalued, trading at <a href="http://pro.benzinga.com/?tblci=GiBHQ5jGSz2tTIA8W0d9W_RJMHgkmUPdKPzylaI48Ac4RiCN1Vcomc3V5NGfyeiJATDviEo">12.85 times forward earnings</a>.
<h2 class="wp-block-heading">Buy-the-Dip Sentiments Could Potentially Boost UNH Stock</h2>
Recently, an investor wrote on the popular <a href="https://www.reddit.com/r/wallstreetbets/comments/1kt8b8d/i_took_100k_from_our_house_sale_and_bought_303/?tblci=GiBHQ5jGSz2tTIA8W0d9W_RJMHgkmUPdKPzylaI48Ac4RiCN1Vcomc3V5NGfyeiJATDviEo" target="_blank" rel="noreferrer noopener">r/wallstreetbets</a>&nbsp;subreddit that he <a href="https://www.benzinga.com/25/05/45668906/americas-not-gonna-stop-getting-sick-says-investor-who-put-100k-into-unh-stock-his-wife-still-thinks-its-sitting-in-a-savings-account">bought $100,000 worth of UNH stock</a>, while deceptively telling his wife that he heeded her instructions to put the money somewhere safe. While there's a cautionary tale here regarding relational integrity, the point as it relates to UnitedHealth is this: investors historically have a tendency of buying the dip in UNH.
Social media isn't the only source for this claim. Following the implosion of UNH stock that started in April and continued into this month, insiders began loading up the truck. To be fair, insider trades aren't the end-all, be-all when it comes to investing decisions. Nevertheless, there's only one reason why insiders buy their own stock: simply, they believe that shares will move higher.
Adding to the intriguing framework is market breadth data, which is the analysis of accumulation (positive sessions) and distribution (negative sessions) patterns. Currently, UNH stock is riding a "3-7-D" sequence: three up weeks, seven down weeks, with a net negative trajectory across the 10-week period. Notably, in 68.75% of cases, the following week's price action results in upside, with a median return of 2.09%.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29152554/UNH-stock-10wk-forecast-1024x576.jpg" alt="" class="wp-image-932195" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29152554/UNH-stock-10wk-forecast-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29152554/UNH-stock-10wk-forecast-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29152554/UNH-stock-10wk-forecast-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29152554/UNH-stock-10wk-forecast.jpg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Image by author</figcaption></figure>
Assuming that UNH stock closes around $297 by the end of this week, the bulls could theoretically push the price above $303 over the next week or two. Should the bulls maintain control of the market, they could drive the price toward the $308 to $310 range over the next several weeks.
<h2 class="wp-block-heading">An Aggressive But Rational Wager For UnitedHealth</h2>
Those willing to gamble on the potential near-term recovery of UnitedHealth may consider the 300/305 bull call spread expiring June 20. This transaction involves buying the $300 call and simultaneously selling the $305 call, for a net debit paid of $235 (the most that can be lost in the trade). Should UNH stock rise through the short strike price at expiration, the maximum reward is $265, or a payout of nearly 113%.
As a fair warning, the above trade is going to be tight because it ultimately comes down to how strong the response will be to the 3-7-D market breadth sequence. For those who want an extra time cushion, traders may consider the 300/305 bull spread for the July 3 expiration date. It's the same transaction but with an additional two weeks of margin.
Plus, the payout for the July 3 spread is quite high at nearly 105%. This defined-risk, defined-reward trade might be a more suitable idea than lying to a spouse about a six-figure investment.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45630622/chwy-stock-short-interest-contrarian-trade">Options Corner: A Contrarian Case Builds As Traders Short Chewy Ahead Of Earnings</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Equities

Options Corner: UnitedHealth May Be Broken But Contrarian Traders Eyeball A Recovery

A Reddit user claims he took $100,000 from a recent <a href="https://www.benzinga.com/personal-finance/financial-advisors/25/04/44658576/more-homes-hit-the-market-but-pending-sales-dip-as-buyers-hesitate">house sale</a> and put it all into UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) stock without telling his wife, who believes the money is safely tucked away in a <a href="https://www.benzinga.com/money/best-high-yield-savings-accounts">high-yield savings account</a>.
<h2 class="wp-block-heading">A High-Stakes Secret</h2>
In the popular <a href="https://www.reddit.com/r/wallstreetbets/comments/1kt8b8d/i_took_100k_from_our_house_sale_and_bought_303/">r/wallstreetbets</a> subreddit, the investor wrote, &#8220;Wife said, ‘Put it somewhere safe.' I said, hold my beer b&#x2A;tch, then funneled $100K into <a href="https://www.benzinga.com/money/fidelity-investments-review">Fidelity</a> and bought 303 shares of UnitedHealth.&#8221;
Don't Miss:
<ul class="wp-block-list">
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
</ul>
He justified the risky move by saying, &#8220;Because America's not gonna stop getting sick. Fat, old, diabetic, stressed out, healthcare is the last thing people cut. And UNH is built like a tank. Major insider buying too.&#8221;
UnitedHealth stock was down over 41% year to date when the UNH investor posted about his investment late May 22.&nbsp;
The r/wallstreetbets comment section exploded with reactions, ranging from jokes about impending divorce to harsh warnings. The top comment read, &#8220;Make sure you put something aside to pay for your divorce lawyer,&#8221; to which OP replied, &#8220;I still have the $20K… it's either for the lawyer or <a href="https://www.benzinga.com/money/options-trading-strategies">call options</a>.&#8221;
Another comment read, &#8220;You don't need a lawyer if there's nothing left to fight over,&#8221; while another person remarked, &#8220;This is the f&#x2A;&#x2A;ing sh&#x2A;t I signed up for,&#8221; reflecting the subreddit's mix of chaos, comedy, and high-risk investing.
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a>
Others chimed in with classic WallStreetBets flair: &#8220;<a href="https://www.benzinga.com/25/05/45308441/risk-appetite-hits-record-high-0dte-options-hit-67-of-total-volumes2-million-average-contracts-in-q1">0dte puts</a> on this guy's marriage at open,&#8221; and &#8220;Big Balls, Big Calls.&#8221;&nbsp;
Critics, though, pointed to the serious implications. &#8220;If a financial decision needs to be hidden from your <a href="https://www.benzinga.com/personal-finance/24/03/37879066/kevin-oleary-warns-couples-maintain-your-own-financial-identity-but-indiana-university-study-say">significant other</a>, that&#8217;s usually a good indication that it&#8217;s dumb,&#8221; one comment noted. Another added, &#8220;That's financial infidelity. Your marriage is done.&#8221;
<h2 class="wp-block-heading">Inside the UNH Crisis</h2>
Meanwhile, UnitedHealth has <a href="https://www.benzinga.com/25/05/45558758/as-unitedhealth-group-lost-an-unthinkable-140-billion-in-market-cap-since-april-analysts-weigh-in-on-the-path-ahead">had a rough stretch</a>. The company missed earnings expectations last quarter and is under pressure from several fronts. It abruptly <a href="https://www.benzinga.com/25/05/45373368/unitedhealth-stock-plunges-names-new-ceo-suspends-2025-guidance">replaced its CEO</a>, Andrew Witty, with former CEO Stephen Hemsley. Hemsley then <a href="https://www.benzinga.com/general/health-care/25/05/45486314/unitedhealth-ceo-other-insiders-buy-millions-in-stock-as-it-sinks-over-23-in-a-week-move-gets-mixed-reaction">bought in $25 million worth of shares</a>, joining other insiders who collectively purchased millions more in stock.
According to <a href="https://www.secform4.com/insider-trading/731766.htm">filings</a> with the Securities and Exchange Commission, board members Timothy Flynn, Kristen Gil and John Noseworthy purchased shares worth $49,786, $1,003,329 and $93,647, respectively. CFO John Rex added another $5 million.
It also remains under a shadow after the December <a href="https://www.benzinga.com/24/12/42322999/unitedhealth-deeply-saddened-and-shocked-by-death-of-brian-thompson-new-york-police-share-update-on-case-with-10k-reward-offered-rockefeller-center-tree-lighting-to-go-on">assassination</a> of its insurance unit CEO, Brian Thompson.&nbsp;
See Also: Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000.</a>
<h2 class="wp-block-heading">Mixed Sentiment From Investors</h2>
Despite all this, some investors see a long-term opportunity. One commenter argued, &#8220;UNH is too big to fail. The stock will go back up over the next couple years.&#8221;
Others are more skeptical. Investment YouTuber Jeremy Lefebvre called the stock &#8220;straight trash&#8221; <a href="https://x.com/HolySmokas/status/1923806928951775450">on X</a>, comparing it to Boeing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) and warning that UnitedHealth is entering a long stretch of regulatory trouble and bad press.
However, the original poster seems to agree with the bulls, doubling down with: &#8220;I'm not finished. Let's see how the stock moves. I will keep you posted.&#8221;
As of now, his wife is still in the dark.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
</ul>
Image: Shutterstock

'America's Not Gonna Stop Getting Sick,' Says Investor Who Put $100K Into UNH Stock. His Wife Still Thinks It's Sitting In A Savings Account

<ul>
<li>NVDA</li>
<li>GLD</li>
<li>TSLA</li>
<li>AAPL</li>
<li>BULL</li>
<li>UNH</li>
<li>QQQ</li>
<li>GOOGL</li>
<li>$BTC</li>
<li>CVNA</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

CVNA

Top 10 Trending Stocks On WallStreetBets As Of May 29, 2025 (Via Swaggy Stocks)

Press Releases

Class Action Filed Against UnitedHealth Group Incorporated (UNH) - July 7, 2025 Deadline to Join – Contact Levi & Korsinsky

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UnitedHealth Group Incorporated of Class Action Lawsuit and Upcoming Deadlines - UNH

United Health Group Incorporated Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - UNH

UNH Investors Have Opportunity to Join UnitedHealth Group Incorporated Fraud Investigation with the Schall Law Firm

Legal

UnitedHealth Group (UNH) Faces New Allegations of Secret Payments to Nursing Homes Amidst Pending Securities Fraud Suit – Hagens Berman

UnitedHealth Group Announces Earnings Release Date

UNITEDHEALTH GROUP INCORPORATED (NYSE: UNH) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds UnitedHealth Group Incorporated Investors of Upcoming Deadline

UnitedHealth Group Updates on Annual Shareholder Meeting, Board Actions

AM Best Revises Outlooks to Negative for UnitedHealth Group Incorporated and Its Subsidiaries

Comments

UnitedHealth Group

UnitedHealth Group (UNH) Opzioni

Loading...

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO